-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Amylyx Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q3 2025.
- Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$34.4M, a 52.7% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$149M, a 42.5% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$302M, a 712% decline from 2023.
- Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $49.3M.
- Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$198M, a 126% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)